Cookies on VetMed Resource

Like most websites we use cookies. This is to ensure that we give you the best experience possible.

 

Continuing to use www.cabi.org  means you agree to our use of cookies. If you would like to, you can learn more about the cookies we use.

VetMed Resource

Veterinary information to support practice, based on evidence and continuing education

Sign up to receive our Veterinary & Animal Sciences e-newsletter, book alerts and offers direct to your inbox.

Results per page:

Search results

Abstract

The objective of this In-vitro study was to evaluate taurolidine as a therapy for transitional cell carcinomas in canine patients. Transitional cell carcinoma (TCC) is the most common cancer of the urinary bladder in dogs and accounts for approximately 2% of reported malignancies in this species....

Author(s)
Byer, B.; Schlein, L.; Rose, B.; Séguin, B.
Publisher
Canadian Veterinary Medical Association, Ottawa, Canada
Citation
Canadian Journal of Veterinary Research, 2020, 84, 2, pp 115-123
Abstract

Analgesic, physiological and biochemical effects of intramuscular (IM) piroxicam and ketamine or intravenous (IV) and/or subcutaneous (SC) local lidocaine in dogs undergoing bone marrow aspiration (BMA) is described. Ten minutes before BMA, groups of 8 dogs each were pre-medicated IM with 0.3 mg/kg ...

Author(s)
Heydarpour, F.; Javdani, M.; Nikousefat, Z.
Publisher
Online Journal of Veterinary Research, Toowoomba, Australia
Citation
Online Journal of Veterinary Research, 2017, 21, 8, pp 453-459
Abstract

Piroxicam has antitumour effects in dogs with cancer, although side effects may limit its use. The purpose of this study was to retrospectively identify factors predisposing cancer-bearing dogs to adverse events (AEs) following piroxicam therapy. Medical records of dogs presented to the Purdue...

Author(s)
Eichstadt, L. R.; Moore, G. E.; Childress, M. O.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2017, 15, 4, pp 1346-1353
Abstract

Background: Reported response rates of transitional cell carcinoma (TCC) in dogs to piroxicam in combination with either mitoxantrone or carboplatin are similar; however, it is unknown whether either drug might provide superior duration of response. Hypothesis/Objectives: To determine if the...

Author(s)
Allstadt, S. D.; Rodriguez, C. O., Jr.; Boostrom, B.; Rebhun, R. B.; Skorupski, K. A.
Publisher
Wiley-Blackwell, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2015, 29, 1, pp 261-267
Abstract

Background: Transitional cell carcinoma is the most common bladder cancer of dogs. Cisplatin combined with piroxicam provides superior response rates, but unacceptable rates of nephrotoxicity. Tavocept is a chemoprotectant that has mitigated cisplatin toxicity and decreased the required...

Author(s)
Henry, C. J.; Flesner, B. K.; Bechtel, S. A.; Bryan, J. N.; Tate, D. J.; Selting, K. A.; Lattimer, J. C.; Bryan, M. E.; Grubb, L.; Hausheer, F.
Publisher
Wiley, Boston, USA
Citation
Journal of Veterinary Internal Medicine, 2018, 32, 1, pp 370-376
Abstract

Osteosarcoma (OSA) in dogs is locally invasive and highly malignant. Distant metastasis is the most common cause of death. To date, the survival rate in dogs with OSA remains poor. The cytotoxic effects of etoposide against canine OSA cell lines, either alone or in combination with piroxicam, have...

Author(s)
Ong, S. M.; Saeki, K.; Kok, M. K.; Tanaka, Y.; Choisunirachon, N.; Yoshitake, R.; Nishimura, R.; Nakagawa, T.
Publisher
Elsevier Ltd, Oxford, UK
Citation
Research in Veterinary Science, 2017, 113, pp 130-135
AbstractFull Text

Transitional cell carcinoma is rare in dogs, with an unfavorable prognosis and life expectancy close to one and a half years. This article aims to describe the diagnosis and therapeutic management in case of transitional cell carcinoma in a twelve-year-old and eight-month-old dog. Clinical signs...

Author(s)
Schefe, S. B.; Basso, P. C.; Mülle, D. C. de M.
Publisher
Pubvet, Maringá, Brazil
Citation
PUBVET, 2020, 14, 7,
Abstract

Canine transitional cell carcinoma (TCC) of the bladder has historically been treated with a combination of chemotherapy, cyclooxygenase inhibitors and radiation therapy. While surgery has been used to treat TCC of the bladder, its efficacy has yet to be established. Thirty-seven client owned dogs...

Author(s)
Marvel, S. J.; Séguin, B.; Dailey, D. D.; Thamm, D. H.
Publisher
Wiley, Oxford, UK
Citation
Veterinary and Comparative Oncology, 2017, 15, 4, pp 1417-1427
Abstract

Bioequivalence study is highly prized to piroxicam (PIRO), since its generic products have been widely used worldwide. The present work was undertaken to explore the pharmacokinetic behaviors and bioequivalence of two branded PIRO tablets in beagle dogs using the supercritical fluid chromatography...

Author(s)
Li XiaoTing; Gao Yan; Liu Jia; Zhang GongTian; Zhang TianHong
Publisher
Elsevier Ltd, Oxford, UK
Citation
Journal of Chromatography, B, 2018, 1100/1101, pp 93-99
Abstract

Objectives: To determine whether doxorubicin-piroxicam combination is safe and has activity against transitional cell carcinoma in dogs. Methods: Data was collected retrospectively from 34 dogs from two institutions over a 6-year period. Signalment, clinical presentation, treatment specifics,...

Author(s)
Robat, C.; Burton, J.; Thamm, D.; Vail, D.
Publisher
Wiley-Blackwell, Oxford, UK
Citation
Journal of Small Animal Practice, 2013, 54, 2, pp 67-74

Refine Results

Sort Order
Author
Geographical Location
Item Type
Language
Organisms
Subject Topics